Phase 3Active, not recruiting
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease
- Sponsor
- Novo Nordisk A/S (Industry)
- Enrolment
- 7,101 enrolled
- Conditions
- Cardiovascular Disease
- Interventions
- Cagrilintide; Semaglutide; Placebo
- Ages
- adults, older adults
- Registry
- NCT05669755
Full record on ClinicalTrials.gov
From the registry
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called "placebo") which has no effect on the body. Which treatment participants will get will be decided by chance. Participant's chance of getting CagriSema or placebo is the same. Participants will inject the study medicine once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for up to 4.5 years.
Primary outcomes
- Time to first occurrence of 3-point major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered